Advertisement

Genentech and Human Longevity Inc. announce multi-year agreement

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

GENENTECH and Human Longevity Inc. signed a multi-year agreement to conduct whole genome sequencing of tens of thousands of de-identified samples provided by Genentech, a member of the Roche Group.

HLI will sequence genomes to 30x coverage and analyze the data. Financial details of the agreement were not disclosed.

HLI is building a comprehensive integrated human genotype and phenotype database, the HLI Knowledgebase, using Illumina’s HiSeq X Ten and HiSeq 2500 sequencing machines and Pac Bio RS II instruments.

Advertisement
Advertisement
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 
Advertisement
Advertisement